Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

DraftKings (NASDAQ: DKNG) is forecasting robust growth in revenue and profitability in 2025. Read More: Earn up to $845 cash ...

Investors must decide how to proceed with Apple near all-time highs and a significant stakeholder selling shares.

The overall value in Carnival stock is compelling here, making it more a buy than a sell or even a hold. This was an industry ...

Entergy has strong growth potential but appears overvalued. See why ETR stock’s favorable regulatory environment and dividend ...

AstraZeneca's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected ...

CAT's Q3 earnings and revenue guidance disappoints, with a weak end-user demand impacting volumes. Shares of the company dip ...

Gary Vaughan from Daily Stock Picks on developing an investing strategy using fundamentals and technical trading.

Here's the complete list of investment and trading ideas for the day. Buy Sansera Engineering shares in the cash segment for ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

CNQ stock is down in recent months. Is a rebound on the way next year? The post Is CNQ Stock a Buy, Sell, or Hold for 2025?

Investors who are skeptical about whether Carnival can sail through a storm could find a reason to disembark and sell the stock now. I believe Carnival is buy-worthy with a good chance the share ...